<SEC-DOCUMENT>0001213900-26-064037.txt : 20260602
<SEC-HEADER>0001213900-26-064037.hdr.sgml : 20260602
<ACCEPTANCE-DATETIME>20260602131653
ACCESSION NUMBER:		0001213900-26-064037
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20260527
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20260602
DATE AS OF CHANGE:		20260602

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OSR Holdings, Inc.
		CENTRAL INDEX KEY:			0001840425
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				845052822
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41390
		FILM NUMBER:		261054682

	BUSINESS ADDRESS:	
		STREET 1:		10900 NE 4TH STREET, SUITE 2300
		CITY:			BELLEVUE
		STATE:			WA
		ZIP:			98004
		BUSINESS PHONE:		425-635-7700

	MAIL ADDRESS:	
		STREET 1:		10900 NE 4TH STREET, SUITE 2300
		CITY:			BELLEVUE
		STATE:			WA
		ZIP:			98004

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bellevue Life Sciences Acquisition Corp.
		DATE OF NAME CHANGE:	20210113
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0293037-8k_osrhold.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:us-roles="http://fasb.org/us-roles/2026" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:OSRH="http://bellevuespac.com/20260527">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02F_US%2DGAAP%2D2026 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_OSRH_bellevuespac.com_20260527 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20260527_20260527 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001840425 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000004" name="dei:EntityCentralIndexKey">0001840425</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="osrh-20260527.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2026-05-27">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-05-27</xbrli:startDate>
        <xbrli:endDate>2026-05-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-05-272026-05-27_custom_CommonStockParValue0.0001PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OSRH:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-05-27</xbrli:startDate>
        <xbrli:endDate>2026-05-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2026-05-272026-05-27_custom_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001840425</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OSRH:RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2026-05-27</xbrli:startDate>
        <xbrli:endDate>2026-05-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_903_edei--DocumentType_c20260527__20260527_zw9f7mPzqthd"><ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 OR 15(d) of The Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event reported):
<span style="text-decoration: underline"><span id="xdx_90D_edei--DocumentPeriodEndDate_c20260527__20260527_zEDPdywBrKTi"><ix:nonNumeric contextRef="AsOf2026-05-27" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">May 27, 2026</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 100%; text-align: center; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90E_edei--EntityRegistrantName_c20260527__20260527_zAkYfPm8CoFa"><ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000011" name="dei:EntityRegistrantName">OSR HOLDINGS, INC.</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--EntityIncorporationStateCountryCode_c20260527__20260527_zbMPFI1NP251"><ix:nonNumeric contextRef="AsOf2026-05-27" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_906_edei--EntityFileNumber_c20260527__20260527_znp2gLJn5Cwf"><ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000013" name="dei:EntityFileNumber">001-41390</ix:nonNumeric></span></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20260527__20260527_zDE2Ii9NMB77"><ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000014" name="dei:EntityTaxIdentificationNumber">84-5052822</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or Other Jurisdiction</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of Incorporation)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityAddressAddressLine1_c20260527__20260527_z4tVuX57WcB7"><ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000015" name="dei:EntityAddressAddressLine1">10900 NE 4th Street</ix:nonNumeric></span>, <span id="xdx_902_edei--EntityAddressAddressLine2_c20260527__20260527_zojQ34czvcx4"><ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000016" name="dei:EntityAddressAddressLine2">Suite 2300</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressCityOrTown_c20260527__20260527_zKfJfPkzApD6"><ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000017" name="dei:EntityAddressCityOrTown">Bellevue</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20260527__20260527_zcq94sP4cKK8"><ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000018" name="dei:EntityAddressStateOrProvince">WA</ix:nonNumeric></span></span></td>
    <td style="width: 2%; text-align: center">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntityAddressPostalZipCode_c20260527__20260527_ztkyd0qyftU7"><ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000019" name="dei:EntityAddressPostalZipCode">98004</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&#8217;s telephone number, including
area code <span style="text-decoration: underline">(<span id="xdx_903_edei--CityAreaCode_c20260527__20260527_zLtqCq1SVOyg"><ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000020" name="dei:CityAreaCode">425</ix:nonNumeric></span>) <span id="xdx_904_edei--LocalPhoneNumber_c20260527__20260527_z3E1d54k4GCj"><ix:nonNumeric contextRef="AsOf2026-05-27" id="Fact000021" name="dei:LocalPhoneNumber">635-7700</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; width: 100%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not Applicable </span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Former Name or Former Address, if Changed Since Last Report)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt">Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.15pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--WrittenCommunications_c20260527__20260527_zN5loLxTY4w8"><ix:nonNumeric contextRef="AsOf2026-05-27" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--SolicitingMaterial_c20260527__20260527_zwW4e3e5DYGg"><ix:nonNumeric contextRef="AsOf2026-05-27" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_908_edei--PreCommencementTenderOffer_c20260527__20260527_zm35usMHlwBk"><ix:nonNumeric contextRef="AsOf2026-05-27" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--PreCommencementIssuerTenderOffer_c20260527__20260527_zrb4qJx2hFKl"><ix:nonNumeric contextRef="AsOf2026-05-27" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Securities registered pursuant to Section
12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_905_edei--Security12bTitle_c20260527__20260527__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_ztBYd765azSd"><ix:nonNumeric contextRef="From2026-05-272026-05-27_custom_CommonStockParValue0.0001PerShareMember" id="Fact000026" name="dei:Security12bTitle">Common stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--TradingSymbol_c20260527__20260527__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zgPP7zGZZcck"><ix:nonNumeric contextRef="From2026-05-272026-05-27_custom_CommonStockParValue0.0001PerShareMember" id="Fact000027" name="dei:TradingSymbol">OSRH</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_905_edei--SecurityExchangeName_c20260527__20260527__us-gaap--StatementClassOfStockAxis__custom--CommonStockParValue0.0001PerShareMember_zHjMAwkwLRcg"><ix:nonNumeric contextRef="From2026-05-272026-05-27_custom_CommonStockParValue0.0001PerShareMember" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  <tr style="background-color: White">
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--Security12bTitle_c20260527__20260527__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember_zC5hpD8hId4l"><ix:nonNumeric contextRef="From2026-05-272026-05-27_custom_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember" id="Fact000029" name="dei:Security12bTitle">Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--TradingSymbol_c20260527__20260527__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember_zwcXhTkcdAG6"><ix:nonNumeric contextRef="From2026-05-272026-05-27_custom_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember" id="Fact000030" name="dei:TradingSymbol">OSRHW</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The <span id="xdx_900_edei--SecurityExchangeName_c20260527__20260527__us-gaap--StatementClassOfStockAxis__custom--RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember_zygB1KYXVDKa"><ix:nonNumeric contextRef="From2026-05-272026-05-27_custom_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember" format="ixt-sec:exchnameen" id="Fact000031" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Emerging growth company <span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20260527__20260527_z2nTkpbtLnL5"><ix:nonNumeric contextRef="AsOf2026-05-27" format="ixt:booleantrue" id="Fact000032" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act. <span id="xdx_908_edei--EntityExTransitionPeriod_c20260527__20260527_zZ5p3DdRENW5"><ix:nonNumeric contextRef="AsOf2026-05-27" format="ixt:booleanfalse" id="Fact000033" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01. Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Asset Purchase Agreement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 27, 2026, OSR Holdings, Inc. (the &#8220;Company&#8221;) entered
into an Asset Purchase Agreement (the &#8220;Asset Purchase Agreement&#8221;) with Vaximm AG (&#8220;Vaximm&#8221;), a clinical-stage
biopharmaceutical company organized under the laws of Switzerland. Vaximm is an indirect subsidiary of the Company, and the Asset Purchase
Agreement constitutes a related party transaction with respect to the Company.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Asset Purchase Agreement was contemplated by, and entered into
in connection with, the Global Exclusive License Agreement, dated April 29, 2026 (the &#8220;License Agreement&#8221;), among the Company,
Vaximm and BCM Europe AG (&#8220;BCME&#8221;), pursuant to which Vaximm granted BCME an exclusive, worldwide license to develop, manufacture
and commercialize products based on VXM01, an oral DNA-based cancer immunotherapy. The License Agreement was previously described in,
and filed as an exhibit to, the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on April 30, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Asset Purchase Agreement is intended to transfer outright ownership
of the underlying intellectual property from Vaximm to the Company, so that the Company becomes the direct holder of such assets and the
direct beneficiary of any future milestone and royalty payments arising therefrom.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the Asset Purchase Agreement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>Vaximm agreed to sell, and the Company agreed to purchase, free and clear of all encumbrances, all of Vaximm&#8217;s right, title
and interest in and to the VXM01 intellectual property family (including the patents and patent applications, know-how, regulatory filings
and clinical data relating to VXM01) and certain related assigned contracts (collectively, the &#8220;Purchased Assets&#8221;).</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>The aggregate purchase price for the Purchased Assets is $30,000,000 (the &#8220;Purchase Price&#8221;), reflecting the fair market
value of the Purchased Assets.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>The Purchase Price becomes due and payable in full on the date on which the first milestone payment is triggered under the License
Agreement (the &#8220;Full Payment Due Date&#8221;), which is the completion of a Phase 2 clinical study of VXM01 in either glioblastoma
(GBM) or pancreatic ductal adenocarcinoma (PDAC). The Company may, in its sole discretion, make one or more voluntary partial payments
prior to that date, each of which reduces the outstanding balance of the Purchase Price on a dollar-for-dollar basis.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>The closing of the transaction will occur upon full payment of the first milestone payment, subject to the satisfaction or waiver
of customary closing conditions, including the delivery of an intellectual property assignment and related transfer instruments.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>A payment default arises solely if the Company fails to pay the outstanding balance of the Purchase Price on the Full Payment Due
Date; no failure to make a voluntary partial payment constitutes a default. Any payment default is subject to a good faith resolution
procedure between the parties before the seller may pursue other remedies, and no payment default affects the validity of the transfer
of the Purchased Assets to the Company.</td></tr></table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"/><td style="width: 0.25in">&#9679;</td><td>The Asset Purchase Agreement may be terminated by either party if the closing has not occurred by December 31, 2027, subject to customary
exceptions.</td></tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Asset Purchase Agreement also contains customary provisions relating
to representations and warranties, covenants, intellectual property registration and maintenance, indemnification, confidentiality, and
dispute resolution, and is governed by the laws of Switzerland.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The foregoing description of the Asset Purchase Agreement does not
purport to be complete and is qualified in its entirety by reference to the full text of the Asset Purchase Agreement, which is filed
as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 9.01. Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>EXHIBIT INDEX</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="ea029303701ex10-1.htm">Asset Purchase Agreement, dated May 27, 2026</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: June 2, 2026</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">OSR HOLDINGS, INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%">&#160;</td>
    <td style="width: 31%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kuk Hyoun Hwang</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&#160;</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kuk Hyoun Hwang</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJyFkN9qwjAUh5/AdzgUL0tNyvSid66ojOksVdxuY3u6BduknMR/j7S3XNpaFDZYCIQkvy/fOfE831vouSyR4OM5XcIWq7oUFiHFAglVhi4Rv7xG4NYUP6WxJJRttz0Ya8egYybBWLjzNnmSBvMI2GTEwlE4AcYj/gTTlTdo7mOtCpmjslKUIFQOCemaJFpB1+6Frbhopatra9ohGalVBDxg3fU3hIyH8KZP4qzpYGC5jL2B346BtyB9rF1qdrGoGhJmJVZOZzr6PttqsqOxuopSzBErsS/xXVDTpZldkDJpmqO5ps2XIDTrwvVbabWxOjtM7S2CCckM1wXnwZgl2GVXWO2RnICzMORsyvrP6T1wvol8wLsKCk1gWhnoArJWB6bxgbDuu/owQt1Ym9CwFUONN/KP9h7KTgTtRHlEFjDG+D/lxg9+H2pBcGpYGHb0b+cP5NW5dA== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ea029303701ex10-1.htm
<DESCRIPTION>ASSET PURCHASE AGREEMENT, DATED MAY 27, 2026
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ASSET PURCHASE
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>by and between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">VAXIMM AG</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(as Seller) and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>OSR HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(as Buyer)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Dated: May
27, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">This <B>ASSET PURCHASE
AGREEMENT</B> (this <B>&ldquo;Agreement&rdquo;</B>), dated as of May 27, 2026 (the <B>&ldquo;Effective Date&rdquo;</B>), is entered into by
and between:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><B>(1)</B></TD><TD STYLE="text-align: left"><B>VAXIMM AG</B>, a company incorporated under the laws of Switzerland, having its registered office at
Hochbergerstrasse 60c, 4057 Basel, Switzerland (<B>&ldquo;Seller&rdquo;</B>); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"><B>(2)</B></TD><TD STYLE="text-align: left"><B>OSR HOLDINGS, INC.</B>, a company incorporated under the laws of the State of Delaware, United States
of America, having its principal office at 10900 NE 4th Street, Suite 2300, Bellevue, WA 98004, U.S.A. (<B>&ldquo;Buyer&rdquo;</B>).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">The Seller and
the Buyer are hereinafter referred to collectively as the &ldquo;Parties&rdquo; and individually as a &ldquo;Party&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <U>RECITALS</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">WHEREAS, the Seller
is a Swiss clinical-stage biopharmaceutical company that has developed certain proprietary immunotherapy technology, including intellectual
property relating to VXM01 (anti-VEGFR2 oral T-cell vaccine) and related pipeline assets;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">WHEREAS, the Buyer
is the parent of OSR Holdings Co., Ltd. (<B>&ldquo;OSRK&rdquo;</B>), a wholly-owning parent of the Seller, and therefore the Seller is
an affiliate of the Buyer by virtue of the Buyer&rsquo;s controlling ownership interest in OSRK, the 100% shareholder of the Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">WHEREAS, the Parties
have entered into a Global Exclusive License Agreement dated April 29, 2026 (the &ldquo;License Agreement&rdquo;) pursuant to which the
Seller has granted to Buyer&rsquo;s affiliate, BCM Europe AG (&ldquo;BCME&rdquo;), an exclusive global license to develop, manufacture,
and commercialize products based on the Purchased Assets (as defined herein);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">WHEREAS, the Parties
intend for the Buyer to acquire outright ownership of the Purchased Assets from the Seller, such that the Buyer shall become the direct
holder of the Purchased Assets and the direct beneficiary of any future milestone and royalty payments arising therefrom, thereby avoiding
potential transfer pricing and tax complications in Switzerland that would otherwise arise if such economic benefits remained with the
Seller;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">WHEREAS, in light
of the affiliated nature of the Parties and the underlying purpose of this transaction as a restructuring of intra-group IP ownership
to avoid transfer pricing complications that would arise in Switzerland only upon the Buyer&rsquo;s actual receipt of revenues derived
from the Purchased Assets, the Parties agree that the full Purchase Price shall be due and payable upon the occurrence of the First Milestone
Payment Trigger under the License Agreement, with the Buyer having the right (but not the obligation) to make voluntary Partial Payments
prior to such date;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">NOW, THEREFORE,
in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, the Parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: left">DEFINITIONS</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">As used in this
Agreement, the following terms shall have the meanings set forth below. Capitalized terms used but not defined herein shall have the meanings
ascribed to them in the License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Affiliate&rdquo;</B>
means, with respect to any Person, any other Person that directly or indirectly controls, is controlled by, or is under common control
with such Person. For purposes of this definition, &ldquo;control&rdquo; means the possession, directly or indirectly, of the power to direct
or cause the direction of the management or policies of a Person, whether through ownership of voting securities, by contract, or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Assigned
Contracts&rdquo;</B> means all agreements, contracts, and arrangements listed in Schedule 2 to which the Seller is a party and which relate
exclusively or primarily to the Purchased Assets, including without limitation sponsored research agreements, material transfer agreements,
clinical trial agreements, and collaboration agreements to the extent transferable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Business
Day&rdquo;</B> means any day other than a Saturday, Sunday, or public holiday in Switzerland or the United States on which commercial banks
in Basel, Switzerland, and Bellevue, Washington, U.S.A., are open for ordinary banking business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.5pt; text-align: left; text-indent: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.5pt; text-align: left; text-indent: 0pt"><B>&ldquo;Closing&rdquo;</B>
has the meaning set forth in Section 3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.5pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.5pt; text-align: left; text-indent: 0pt"><B>&ldquo;Closing
Date&rdquo;</B> has the meaning set forth in Section 3.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.5pt; text-align: left; text-indent: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.5pt; text-align: left; text-indent: 0pt"><B>&ldquo;Default
Notice&rdquo;</B> has the meaning set forth in Section 5.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Encumbrance&rdquo;</B>
means any mortgage, charge, pledge, lien, option, right of pre-emption, assignment by way of security, retention of title, trust arrangement,
or other security interest or encumbrance of any nature whatsoever, or any agreement to create any of the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;First
Milestone Payment Trigger&rdquo;</B> means the event giving rise to the first milestone payment obligation under the License Agreement,
being the completion of a Phase 2 clinical study of VXM01 in either glioblastoma (GBM) or pancreatic ductal adenocarcinoma (PDAC), as
more particularly described in the License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Governmental
Authority&rdquo;</B> means any national, federal, state, provincial, cantonal, municipal, or local government, governmental authority,
regulatory or administrative agency, governmental commission, department, board, bureau, agency or instrumentality, court, tribunal, arbitrator,
or arbitral body.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Full
Payment Due Date&rdquo;</B> means the date on which the First Milestone Payment Trigger occurs (or, if such date is not a Business Day,
the next succeeding Business Day), on which date the full outstanding balance of the Purchase Price (i.e., the full USD 30,000,000 less
the aggregate of all Partial Payments previously received by the Seller) shall become due and payable in accordance with Section 5.2.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Intellectual
Property Rights&rdquo;</B> means all intellectual property rights anywhere in the world, whether registered or unregistered, including:
(a) patents, utility models, and rights in inventions; (b) trademarks, service marks, trade names, business names, and domain names; (c)
copyright and related rights; (d) rights in designs; (e) rights in know-how, trade secrets, and confidential information; and (f) all
applications for and rights to apply for any of the foregoing, together with all rights to sue for past infringement thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Know-How&rdquo;</B>
means all technical information, data, results, processes, methods, protocols, formulations, and other proprietary information that is
owned by or licensed to the Seller and relates to the VXM01 IP Family, to the extent not published or in the public domain as of the Effective
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.5pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;License
Agreement&rdquo;</B> has the meaning ascribed thereto in the Recitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18.5pt; text-align: left; text-indent: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Payment
Default&rdquo;</B> has the meaning set forth in Section 5.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Partial
Payment&rdquo;</B> means any voluntary payment made by the Buyer to the Seller on account of the Purchase Price at any time prior to the
Full Payment Due Date, in accordance with Section 5.2. All Partial Payments shall be tallied and accumulated, and shall reduce the outstanding
balance of the Purchase Price accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Person&rdquo;</B>
means any natural person, corporation, company, partnership, limited liability company, joint venture, trust, estate, association, Governmental
Authority, or other entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B></B></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Purchase
Price&rdquo;</B> has the meaning set forth in Section 5.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Purchased
Assets&rdquo;</B> means, collectively, all right, title, and interest of the Seller in and to the VXM01 IP Family and the Assigned Contracts,
as more particularly described in Schedule 1 and Schedule 2, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;Regulatory
Approvals&rdquo;</B> means all approvals, permits, registrations, authorizations, and clearances issued by any Governmental Authority required
for the development, manufacture, or commercialization of VXM01 or any product based thereon, including investigational new drug applications,
clinical trial authorizations, and marketing authorizations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: left; text-indent: 0pt"><B>&ldquo;VXM01
IP Family&rdquo;</B> means all Intellectual Property Rights owned by the Seller or in which the Seller has a licensable interest that relate
to VXM01 (anti-VEGFR-2 oral T-cell vaccine) and its development, including, without limitation: (a) the patents and patent applications
listed in Schedule 1; (b) all continuation, divisional, continuation-in-part, reissue, reexamination, and extension applications claiming
priority thereto; (c) all Know-How; (d) all regulatory filings, Regulatory Approvals, and clinical data; (e) all laboratory notebooks,
research materials, and biological materials; and (f) all goodwill associated with any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-indent: 0pt">2. SALE AND PURCHASE OF ASSETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">2.1</TD><TD STYLE="text-align: left">Sale and Purchase</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">Subject to the
terms and conditions of this Agreement, at the Closing, the Seller hereby agrees to sell, transfer, convey, assign, and deliver to the
Buyer, and the Buyer hereby agrees to purchase and accept from the Seller, free and clear of all Encumbrances, all of the Seller&rsquo;s right,
title, and interest in and to the Purchased Assets.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">2.2</TD><TD STYLE="text-align: left">Excluded Assets</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">For the avoidance
of doubt, the Purchased Assets shall not include: (a) any cash or cash equivalents of the Seller; (b) accounts receivable of the Seller
arising prior to the Closing Date; (c) any corporate books, records, or organizational documents of the Seller; (d) any assets of the
Seller unrelated to the VXM01 IP Family; or (e) any contracts or agreements that relate to the Seller&rsquo;s business generally and are not
exclusively related to the Purchased Assets.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">2.3</TD><TD STYLE="text-align: left">Assumed Obligations</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">Effective upon
the Closing, the Buyer shall assume and agrees to pay, perform, discharge, and be solely responsible for all obligations and liabilities
arising under the Assigned Contracts from and after the Closing Date. Other than as set forth in this Section 2.3, the Buyer shall not
assume and shall not be liable for any liabilities or obligations of the Seller of any kind or nature.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">2.4</TD><TD STYLE="text-align: left">Consents and Approvals</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">To the extent
that the assignment of any Assigned Contract requires the consent of a third party and such consent has not been obtained prior to the
Closing, this Agreement shall not constitute or be deemed to constitute an assignment or an attempted assignment thereof until such consent
is obtained. The Seller shall use commercially reasonable efforts to obtain all such consents prior to or as soon as practicable after
the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: left">CLOSING</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">3.1</TD><TD STYLE="text-align: left">Closing Date</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">The closing of
the transactions contemplated by this Agreement (the &ldquo;Closing&rdquo;) shall take place remotely via the exchange of electronic documents
on the date of a full payment of the First Milestone Payment, or such other date as the Parties may agree in writing (the &ldquo;Closing
Date&rdquo;).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">3.2</TD><TD STYLE="text-align: left">Seller&rsquo;s Closing Deliverables</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">At the Closing,
the Seller shall deliver or cause to be delivered to the Buyer each of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: left">an intellectual property assignment agreement in a form mutually agreed by the Parties, duly executed
by the Seller, assigning to the Buyer all rights in the VXM01 IP Family (the &ldquo;IP Assignment&rdquo;);</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: left">an assignment and assumption agreement in respect of the Assigned Contracts, in a form mutually agreed
by the Parties, duly executed by the Seller;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: left">a bill of sale with respect to any tangible personal property included in the Purchased Assets, duly executed
by the Seller;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: left">copies of all consents, approvals, waivers, and authorizations required in connection with the Closing;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: left">a complete and accurate copy of all Know-How in the Seller&rsquo;s possession or control; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: left">such other instruments of transfer, assignment, assumption, and conveyance as the Buyer may reasonably
request.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">3.3</TD><TD STYLE="text-align: left">Buyer&rsquo;s Closing Deliverables</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">At the Closing, the Buyer shall
deliver or cause to be delivered to the Seller each of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: left">the assignment and assumption agreement referred to in Section 3.2(b), duly executed by the Buyer;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: left">a written acknowledgment of receipt of the Purchased Assets; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: left">a written undertaking by the Buyer acknowledging the Purchase Price and its obligation to make payment
thereof in accordance with Section 5.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: left">REPRESENTATIONS AND WARRANTIES</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">4.1</TD><TD STYLE="text-align: left">Representations and Warranties of the Seller</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">The Seller represents
and warrants to the Buyer as of the Effective Date and the Closing Date as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: left">Organization and Qualification. The Seller is a company duly incorporated, validly existing, and in good
standing under the laws of Switzerland, with full corporate power and authority to conduct its business as currently conducted.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: left">Authorization. The execution, delivery, and performance of this Agreement by the Seller have been duly
authorized by all necessary corporate action. This Agreement constitutes a legal, valid, and binding obligation of the Seller, enforceable
against it in accordance with its terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: left">Title to Purchased Assets. The Seller owns and has the right to sell and transfer the Purchased Assets
to the Buyer, free and clear of all Encumbrances. Upon the Closing, the Buyer will acquire good and valid title to the Purchased Assets,
free and clear of all Encumbrances.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: left">Intellectual Property. To the Seller&rsquo;s knowledge, the VXM01 IP Family is valid and subsisting. The Seller
has not received any written notice of any claim that any of the patents included in the VXM01 IP Family is invalid or unenforceable or
that the development or commercialization of VXM01 infringes the intellectual property rights of any third party.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(e)</TD><TD STYLE="text-align: left">No Conflicts. The execution and delivery of this Agreement and the consummation of the transactions contemplated
hereby will not: (i) conflict with or violate the organizational documents of the Seller; (ii) conflict with or violate any law or regulation
applicable to the Seller; or (iii) result in any breach or violation of any material agreement to which the Seller is a party.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(f)</TD><TD STYLE="text-align: left">No Litigation. There is no pending or, to the Seller&rsquo;s knowledge, threatened action, suit, proceeding,
or investigation before any court or Governmental Authority that would materially and adversely affect the Purchased Assets or the ability
of the Seller to consummate the transactions contemplated by this Agreement.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">4.2</TD><TD STYLE="text-align: left">Representations and Warranties of the Buyer</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">The Buyer represents
and warrants to the Seller as of the Effective Date and the Closing Date as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: left">Organization. The Buyer is a company duly incorporated, validly existing, and in good standing under the
laws of the State of Delaware, United States of America.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: left">Authorization. The execution, delivery, and performance of this Agreement by the Buyer have been duly
authorized by all necessary corporate action. This Agreement constitutes a legal, valid, and binding obligation of the Buyer, enforceable
against it in accordance with its terms.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: left">Financial Capacity. The Buyer has, or will have at the Full Payment Due Date, sufficient financial resources
to pay the full outstanding balance of the Purchase Price when due, or the ability to obtain such resources through its parent company
or other affiliated entities.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: left">No Conflicts. The execution and delivery of this Agreement and the consummation of the transactions contemplated
hereby will not conflict with any obligation of the Buyer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: left">PURCHASE PRICE AND PAYMENT</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left">5.1</TD><TD STYLE="text-align: left">Purchase Price</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">The aggregate
consideration payable by the Buyer to the Seller for the Purchased Assets shall be thirty million United States dollars (USD 30,000,000)
(the &ldquo;Purchase Price&rdquo;), payable in full on the Full Payment Due Date as set forth in Section 5.2, subject to reduction by
any Partial Payments made prior thereto. The Parties acknowledge and agree that the Purchase Price reflects the fair market value of the
Purchased Assets as determined by the Parties through arm&rsquo;s length negotiation, consistent with transfer pricing principles applicable
under Swiss law.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">5.2</TD><TD STYLE="text-align: left">Payment; Partial Payments</TD>
</TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: left">Full Payment on Full Payment Due Date. The full outstanding balance of the Purchase Price (i.e., USD 30,000,000
less the aggregate amount of all Partial Payments, if any, previously received by the Seller) shall be due and payable in full on the
Full Payment Due Date. The Parties acknowledge that the Swiss transfer pricing considerations underlying this Agreement are triggered
only upon the Buyer&rsquo;s actual receipt of revenues derived from the Purchased Assets, and accordingly there is no commercial or regulatory
necessity to require payment prior to the Full Payment Due Date.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: left">Partial Payments. Notwithstanding Section 5.2(a), the Buyer may, at its sole discretion, make one or more
Partial Payments to the Seller at any time prior to the Full Payment Due Date. Each Partial Payment shall be made by wire transfer of
immediately available funds to the bank account designated in Schedule 3. All Partial Payments shall be tallied and accumulated, shall
be nonrefundable, and shall reduce, on a dollar-for-dollar basis, the outstanding balance of the Purchase Price remaining due on the Full
Payment Due Date. The Seller shall provide the Buyer with a written acknowledgment of each Partial Payment received within five (5) Business
Days of receipt, together with a statement of the then-outstanding balance of the Purchase Price.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: left">Notification of First Milestone Payment Trigger. The Seller shall promptly notify the Buyer in writing
upon becoming aware that the First Milestone Payment Trigger has occurred or is reasonably anticipated to occur within sixty (60) days,
so that the Buyer has adequate advance notice to prepare for the Full Payment. Any payment due on the Full Payment Due Date shall be made
by wire transfer of immediately available funds to the bank account designated in Schedule 3.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left"><B>5.3</B></TD><TD STYLE="text-align: left"><B>Payment Default; Good Faith Resolution</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36.05pt; text-align: left; text-indent: -18.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: left">A &ldquo;Payment Default&rdquo; shall occur solely and exclusively
if the Buyer fails to pay the full outstanding balance of the Purchase Price (i.e., USD 30,000,000 less the aggregate of all Partial
Payments previously received by the Seller) on the Full Payment Due Date. For the avoidance of doubt, no failure or delay by the Buyer
in making any Partial Payment prior to the Full Payment Due Date shall constitute a Payment Default or give rise to any remedy or claim
by the Seller hereunder, it being the Parties&rsquo; express intention that the Buyer&rsquo;s only mandatory payment obligation is the
payment of the full outstanding balance on the Full Payment Due Date. Upon the occurrence of a Payment Default, the Seller may deliver
written notice to the Buyer specifying the amount outstanding (a &ldquo;Default Notice&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: left">The Parties acknowledge the affiliated relationship between the Seller and the Buyer and the underlying
purpose of this Agreement as an intra-group restructuring of IP ownership to avoid transfer pricing complications in Switzerland. In recognition
thereof, the Parties agree that any Payment Default shall be addressed through the following good faith resolution procedure:</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: left">within thirty (30) days of the Seller&rsquo;s delivery of a
Default Notice, the authorized senior representatives of both Parties shall meet (in person or by video conference) to discuss the Payment
Default in good faith and to explore options for resolving the outstanding balance;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.55pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 1.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: left">(ii)</TD>
    <TD STYLE="text-align: left">the Parties shall use commercially reasonable
efforts to negotiate and agree, within sixty (60) days of the Default Notice (the &ldquo;Resolution Period&rdquo;), a mutually acceptable
written amendment to the payment terms of this Agreement, which may include, without limitation, an extension of the Full Payment Due
Date, a revised payment schedule, or such other modifications as the Parties deem appropriate in the circumstances, taking into account
their respective commercial interests and the ongoing parent-subsidiary relationship; and</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.55pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 1.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: left">any agreed resolution shall be documented in a written amendment
to this Agreement executed by duly authorized representatives of both Parties.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.55pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD STYLE="text-align: left">If the Parties are unable to reach agreement on a revised payment arrangement within the Resolution Period,
the Seller may, in its sole discretion, pursue any remedy available to it at law or in equity; provided, however, that: (i) the Seller
shall not seek to unwind the transfer of the Purchased Assets to the Buyer or take any action that would defeat the tax and transfer pricing
objectives underlying this Agreement without first obtaining an independent legal opinion confirming that such unwinding would not itself
create adverse tax or regulatory consequences for either Party; and (ii) the Parties shall, at the Seller&rsquo;s election, submit any
unresolved dispute to binding arbitration in accordance with Section 11.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD STYLE="text-align: left">For the avoidance of doubt, in no event shall any Payment Default (whether or not cured) affect the validity
of the transfer of the Purchased Assets to the Buyer or the Buyer&rsquo;s ownership rights therein upon Closing.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">5.4</TD><TD STYLE="text-align: left">Taxes</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">Each Party shall
be responsible for any taxes imposed on it by applicable law as a result of this transaction. The Parties shall cooperate in good faith
to structure the transaction in a manner that minimizes any adverse tax consequences to either Party, and shall use commercially reasonable
efforts to obtain any available exemptions from withholding or similar taxes. The Buyer shall be responsible for any stamp duty, transfer
tax, or registration fees arising from the transfer of the Purchased Assets to the Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in; text-align: left">6.</TD><TD STYLE="text-align: left">INTELLECTUAL PROPERTY REGISTRATION AND MAINTENANCE</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">6.1</TD><TD STYLE="text-align: left">Recordal of Assignment</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">As soon as practicable
following the Closing, the Buyer (or its designated agent) shall, at the Buyer&rsquo;s expense, take all steps necessary to record the assignment
of the VXM01 IP Family from the Seller to the Buyer with the relevant patent offices and intellectual property registries worldwide, including
but not limited to the European Patent Office, the United States Patent and Trademark Office, and each national patent office in which
any patent or patent application included in the VXM01 IP Family is pending or registered.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">6.2</TD><TD STYLE="text-align: left">Maintenance Obligations</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">From and after
the Closing Date, the Buyer shall be solely responsible for the prosecution, maintenance, and enforcement of all Intellectual Property
Rights included in the VXM01 IP Family at the Buyer&rsquo;s sole cost and expense. The Seller shall provide reasonable assistance to the Buyer
in connection with any such activities, including the execution of any additional instruments or documents, at the Buyer&rsquo;s reasonable
request and cost.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">6.3</TD><TD STYLE="text-align: left">Pre-Closing Maintenance</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">Prior to the Closing
Date, the Seller shall maintain the Purchased Assets in good standing and shall not abandon, disclaim, or allow to lapse any patent, patent
application, or registration included in the VXM01 IP Family without the prior written consent of the Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in; text-align: left">7.</TD><TD STYLE="text-align: left">COVENANTS</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">7.1</TD><TD STYLE="text-align: left">Pre-Closing Covenants of Seller</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">During the period
from the Effective Date until the Closing Date, the Seller covenants that it shall: (a) not sell, transfer, assign, license (other than
pursuant to the License Agreement), pledge, or otherwise dispose of or Encumber any of the Purchased Assets; (b) not amend or modify the
License Agreement in any way that would materially adversely affect the Purchased Assets; (c) promptly notify the Buyer of any event or
circumstance that would or could reasonably be expected to materially and adversely affect the Purchased Assets; and (d) use commercially
reasonable efforts to preserve the goodwill and business relationships associated with the Purchased Assets.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.3in; text-align: left">7.2</TD><TD STYLE="text-align: left">Further Assurances</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">Each Party agrees
to execute and deliver, at the reasonable request and expense of the requesting Party, such additional instruments, documents, and agreements,
and to take such other actions as may be reasonably required to carry out the intent of this Agreement and consummate the transactions
contemplated hereby.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">7.3</TD><TD STYLE="text-align: left">Confidentiality</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">Each Party agrees
to keep confidential the terms and conditions of this Agreement (other than the existence of the transaction). Notwithstanding the foregoing,
either Party may disclose the terms of this Agreement: (a) to its professional advisors, auditors, and financiers who are bound by confidentiality
obligations no less restrictive than those set out herein; (b) as required by applicable law or regulation or by the rules of any stock
exchange on which such Party&rsquo;s securities are listed; or (c) with the prior written consent of the other Party.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">7.4</TD><TD STYLE="text-align: left">Cooperation on Tax Matters</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">The Parties shall
cooperate in good faith with respect to any inquiry, audit, or proceeding by any Governmental Authority relating to the tax treatment
of the transactions contemplated by this Agreement, including any Swiss Federal Tax Administration inquiry relating to transfer pricing.
Each Party shall promptly notify the other of any such inquiry or proceeding and shall not settle or compromise any such matter without
the other Party&rsquo;s prior written consent (not to be unreasonably withheld, conditioned, or delayed).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in; text-align: left">8.</TD><TD STYLE="text-align: left">INDEMNIFICATION</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">8.1</TD><TD STYLE="text-align: left">Indemnification by the Seller</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">The Seller shall
indemnify, defend, and hold harmless the Buyer and its directors, officers, employees, agents, and successors from and against any and
all losses, liabilities, damages, costs, and expenses (including reasonable legal fees) arising out of or resulting from: (a) any breach
of any representation, warranty, or covenant of the Seller contained in this Agreement; (b) any liability of the Seller relating to the
Purchased Assets arising from events or circumstances occurring prior to the Closing Date; or (c) any failure by the Seller to perform
its obligations under this Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">8.2</TD><TD STYLE="text-align: left">Indemnification by the Buyer</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">The Buyer shall
indemnify, defend, and hold harmless the Seller and its directors, officers, employees, agents, and successors from and against any and
all losses, liabilities, damages, costs, and expenses (including reasonable legal fees) arising out of or resulting from: (a) any breach
of any representation, warranty, or covenant of the Buyer contained in this Agreement; (b) any liability of the Buyer relating to the
Purchased Assets arising from events or circumstances occurring on or after the Closing Date; or (c) any failure by the Buyer to perform
the Assumed Obligations.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">8.3</TD><TD STYLE="text-align: left">Indemnification Procedure</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">The Party seeking
indemnification (the &ldquo;Indemnified Party&rdquo;) shall promptly notify the indemnifying party (the &ldquo;Indemnifying Party&rdquo;)
in writing of any claim for which indemnification is sought. The Indemnifying Party shall have the right to assume control of the defense
of any such claim with counsel reasonably acceptable to the Indemnified Party. The Indemnified Party shall cooperate in good faith in
the defense of any such claim and shall not settle any such claim without the prior written consent of the Indemnifying Party.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">8.4</TD><TD STYLE="text-align: left">Limitations</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">Notwithstanding
anything to the contrary in this Agreement: (a) neither Party&rsquo;s aggregate liability under this Section 8 shall exceed the Purchase Price;
and (b) neither Party shall be liable for any indirect, consequential, special, punitive, or exemplary damages, regardless of the form
of action; provided that these limitations shall not apply in the case of fraud or willful misconduct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in; text-align: left">9.</TD><TD STYLE="text-align: left">CONDITIONS TO CLOSING</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">9.1</TD><TD STYLE="text-align: left">Conditions to Each Party&rsquo;s Obligations</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">The respective
obligations of each Party to consummate the transactions contemplated by this Agreement are subject to the satisfaction or waiver by both
Parties of the following conditions: (a) no Governmental Authority shall have enacted, issued, promulgated, enforced, or entered any law,
rule, regulation, order, or injunction that prohibits or makes illegal the consummation of the transactions contemplated by this Agreement;
and (b) no action, suit, or proceeding shall be pending before any Governmental Authority seeking to enjoin or restrain the consummation
of the transactions contemplated hereby.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">9.2</TD><TD STYLE="text-align: left">Conditions to Buyer&rsquo;s Obligations</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">The obligation
of the Buyer to consummate the transactions contemplated by this Agreement is subject to the satisfaction or waiver by the Buyer of the
following additional conditions: (a) the representations and warranties of the Seller set forth in Section 4.1 shall be true and correct
in all material respects as of the Closing Date; (b) the Seller shall have performed and complied in all material respects with each of
its obligations and covenants required to be performed or complied with by it under this Agreement prior to or at the Closing; and (c)
the Seller shall have delivered all items required under Section 3.2.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">9.3</TD><TD STYLE="text-align: left">Conditions to Seller&rsquo;s Obligations</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">The obligation
of the Seller to consummate the transactions contemplated by this Agreement is subject to the satisfaction or waiver by the Seller of
the following additional conditions: (a) the representations and warranties of the Buyer set forth in Section 4.2 shall be true and correct
in all material respects as of the Closing Date; (b) the Buyer shall have performed and complied in all material respects with each of
its obligations and covenants required to be performed or complied with by it under this Agreement prior to or at the Closing; and (c)
the Buyer shall have delivered all items required under Section 3.3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in; text-align: left">10.</TD><TD STYLE="text-align: left">TERMINATION</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">10.1</TD><TD STYLE="text-align: left">Termination Prior to Closing</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">This Agreement
may be terminated prior to the Closing: (a) by mutual written consent of the Parties; (b) by either Party, if the Closing has not occurred
by December 31, 2027 (the &ldquo;Termination Date&rdquo;), provided that the right to terminate shall not be available to a Party whose
breach of this Agreement has caused or materially contributed to the failure to close; or (c) by either Party, if any Governmental Authority
has issued a final, non-appealable order permanently enjoining or prohibiting the consummation of the transactions contemplated by this
Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">10.2</TD><TD STYLE="text-align: left">Effect of Termination</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">In the event of
the termination of this Agreement pursuant to Section 10.1, this Agreement shall become null and void and of no further force or effect;
provided that: (a) the obligations of confidentiality in Section 7.3 and the general provisions in Section 11 shall survive any termination;
and (b) no termination shall relieve any Party of any liability for any breach of this Agreement occurring prior to such termination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in; text-align: left">11.</TD><TD STYLE="text-align: left">GENERAL PROVISIONS</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">11.1</TD><TD STYLE="text-align: left">Governing Law</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">This Agreement
shall be governed by and construed in accordance with the laws of Switzerland, without regard to its conflicts of law provisions.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">11.2</TD><TD STYLE="text-align: left">Dispute Resolution</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">Any dispute, controversy,
or claim arising out of or in relation to this Agreement, including the validity, invalidity, breach, or termination thereof, shall be
first submitted to senior management of both Parties for good faith negotiation for a period of thirty (30) days. If the dispute cannot
be resolved by negotiation, it shall be finally resolved by arbitration in accordance with the Swiss Rules of International Arbitration
of the Swiss Arbitration Centre in force on the date on which the Notice of Arbitration is submitted in accordance with these Rules. The
number of arbitrators shall be three (3). The seat of arbitration shall be Zurich, Switzerland. The arbitral proceedings shall be conducted
in the English language.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">11.3</TD><TD STYLE="text-align: left">Notices</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">All notices, requests,
demands, consents, and other communications required or permitted under this Agreement shall be in writing and shall be deemed duly given:
(a) when delivered personally; (b) one (1) Business Day after being sent by internationally recognized overnight courier service; or (c)
upon receipt of electronic confirmation when sent by email (with a copy sent by overnight courier), to the addresses set forth below or
to such other address as a Party may designate by notice:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left; text-indent: 0pt">If to the Seller:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left; text-indent: 0pt">VAXIMM AG</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left; text-indent: 0pt">Hochbergerstrasse
60c, 4057 Basel, Switzerland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left; text-indent: 0pt">Attention: Andreas
Niethammer, CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left; text-indent: 0pt">Email: andreas.niethammer@vaximm.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left; text-indent: 0pt">If to the Buyer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left; text-indent: 0pt">OSR HOLDINGS,
INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left; text-indent: 0pt">Attention: Yeiseok
Kim, COO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1.25in; text-align: left; text-indent: 0pt">Email: jessi.kim@osr-holdings.com</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">11.4</TD><TD STYLE="text-align: left">Entire Agreement; Amendments</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">This Agreement,
together with the Schedules hereto, constitutes the entire agreement between the Parties with respect to the subject matter hereof and
supersedes all prior or contemporaneous understandings, agreements, negotiations, representations, and warranties, whether written or
oral, with respect thereto. No amendment, modification, or supplement to this Agreement shall be binding unless made in writing and duly
executed by authorized representatives of both Parties.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">11.5</TD><TD STYLE="text-align: left">Relationship with License Agreement</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">This Agreement
is complementary to, and shall be read in conjunction with, the License Agreement. In the event of any conflict or inconsistency between
this Agreement and the License Agreement with respect to the subject matter of this Agreement, the terms of this Agreement shall prevail.
The Purchase Price obligations set forth herein are independent from, and in addition to, any obligations arising under the License Agreement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">11.6</TD><TD STYLE="text-align: left">Waiver</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">No failure or
delay by either Party in exercising any right, power, or remedy shall operate as a waiver thereof, nor shall any single or partial exercise
of any right, power, or remedy preclude any other or further exercise thereof or the exercise of any other right, power, or remedy.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">11.7</TD><TD STYLE="text-align: left">Severability</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">If any provision
of this Agreement is or becomes invalid, illegal, or unenforceable in any respect under applicable law, the validity, legality, and enforceability
of the remaining provisions shall not in any way be affected or impaired thereby, and the Parties shall negotiate in good faith to modify
this Agreement so as to give effect to the original intent of the Parties to the greatest extent possible.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">11.8</TD><TD STYLE="text-align: left">Assignment</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">Neither Party
may assign this Agreement or any of its rights or obligations hereunder without the prior written consent of the other Party, which consent
shall not be unreasonably withheld or delayed; provided, however, that either Party may, without such consent, assign this Agreement to
any Affiliate or in connection with a merger, acquisition, or sale of all or substantially all of its assets to which this Agreement relates.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">11.9</TD><TD STYLE="text-align: left">Counterparts</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">This Agreement
may be executed in one or more counterparts, each of which shall be deemed an original, and all of which together shall constitute one
and the same instrument. Electronic signatures shall be deemed valid and binding to the same extent as original signatures.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">11.10</TD><TD STYLE="text-align: left">Language</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">This Agreement
is made in the English language. In the event of any conflict between an English version and any translation of this Agreement, the English
version shall prevail.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 17.75pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.35in; text-align: left">11.11</TD><TD STYLE="text-align: left">No Third Party Beneficiaries</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.6in; text-align: left; text-indent: 0pt">This Agreement
is for the sole benefit of the Parties hereto and their respective permitted successors and assigns. Nothing in this Agreement shall create
or be deemed to create any rights in any Person not a party to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0pt"><U>SIGNATURE PAGE</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">IN WITNESS WHEREOF,
the Parties have caused this Agreement to be executed by their respective duly authorized representatives as of the date first written
above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><B>VAXIMM AG</B></TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2"><B>OSR HOLDINGS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">(&ldquo;Seller&rdquo;)</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">(&ldquo;Buyer&rdquo;)</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">/s/ Andreas Niethammer</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">/s/ Yeiseok Kim</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-top: Black 1.5pt solid"><I>Signature</I></TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-top: Black 1.5pt solid"><I>Signature</I></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 35%">Andreas Niethammer</TD>
  <TD STYLE="width: 20%">&nbsp;</TD>
  <TD STYLE="width: 5%">Name:</TD>
  <TD STYLE="width: 35%"> Yeiseok Kim</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Title:</TD>
  <TD>Chief Executive Officer</TD>
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD> Chief Operating Officer</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Date:</TD>
  <TD> May 27, 2026</TD>
  <TD>&nbsp;</TD>
  <TD>Date:</TD>
  <TD>May 27, 2026</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center; text-indent: 0pt">SCHEDULE 1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center; text-indent: 0pt">VXM01 IP FAMILY
&mdash; PATENT SCHEDULE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">The following patents
and patent applications, together with all continuations, divisionals, continuationsin-part, reissues, reexaminations, extensions, and
foreign equivalents thereof, form part of the VXM01 IP Family transferred pursuant to this Agreement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; width: 17%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Patent
    /<BR>
    Application No.</U></B></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; width: 35%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    / Subject Matter</B></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; width: 17%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Territory</B></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; width: 14%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiry</B></FONT></TD>
    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; width: 17%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="5" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
    1 &#8212; Manufacturing: WO 2013/091898</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>US
    9,493,738</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    for Producing High Yield Attenuated Salmonella Strains</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21/12/2032</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EP
    2,794,849</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    for Producing High Yield Attenuated Salmonella Strains</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP
    (BE, CH, DE, DK, ES, FR, GB, IE, IT, NL, PL, SE)</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21/12/2032</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JP
    6,251,179</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    for Producing High Yield Attenuated Salmonella Strains</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21/12/2032</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>KR
    10-2015932</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    for Producing High Yield Attenuated Salmonella Strains</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Korea</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21/12/2032</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CN
    104066834</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    for Producing High Yield Attenuated Salmonella Strains</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21/12/2032</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>AU
    2012359166</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    for Producing High Yield Attenuated Salmonella Strains</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21/12/2032</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CA
    2,853,656</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    for Producing High Yield Attenuated Salmonella Strains</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21/12/2032</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>IN
    313960</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    for Producing High Yield Attenuated Salmonella Strains</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21/12/2032</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>ZA
    2014/04501</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Method
    for Producing High Yield Attenuated Salmonella Strains</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Africa</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21/12/2032</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="5" STYLE="border-bottom: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
    2 &#8212; VXM01 Dosing: WO 2014/005683</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>US
    9,415,098</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    Vaccine for Use in Pancreatic Cancer Patients</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26/06/2033</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>US
    10,293,037</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    Vaccine for Use in Pancreatic Cancer Patients (CON)</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26/06/2033</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>EP
    2,869,836</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    Vaccine for Use in Pancreatic Cancer Patients</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP
    (BE, CH, DE, DK, ES, FR, GB, IE, IT, NL, PL, SE)</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26/06/2033</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>JP
    6,325,534</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    Vaccine for Use in Pancreatic Cancer Patients</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26/06/2033</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>KR
    10-2090612</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    Vaccine for Use in Pancreatic Cancer Patients</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Korea</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26/06/2033</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>CN
    104519908</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    Vaccine for Use in Pancreatic Cancer Patients</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26/06/2033</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>AU
    2013286335</U></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    Vaccine for Use in Pancreatic Cancer Patients</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26/06/2033</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    /<BR>
    Application No.</B></FONT></TD>
    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    / Subject Matter</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Territory</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiry</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD></TR>

  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU
    2017258877</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    Vaccine for Use in Pancreatic Cancer Patients (DIV)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26/06/2033</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA
    2,877,938</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    Vaccine for Use in Pancreatic Cancer Patients</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26/06/2033</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
    180/DELNP/2015</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    Vaccine for Use in Pancreatic Cancer Patients</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26/06/2033</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA
    2014/09156</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DNA
    Vaccine for Use in Pancreatic Cancer Patients</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Africa</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">26/06/2033</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="5" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
    5 &#8212; VXM01 Combination Therapy: WO 2016/202459</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    10,905,752</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    17/107,203</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy (CON)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pending</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP
    3,310,379</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP
    (BE, CH, DE, DK, ES, FR, GB, IE, IT, NL, PL, SE)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP
    3,626,262</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy (DIV)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP
    (CH, ES, GB, IE, NO, PL + Unitary Patent)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP
    2017-565248</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR
    10-2018-7001398</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Korea</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    Examination</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR
    10-2025-7001040</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy (DIV)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Korea</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN
    107995868</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU
    2016278588</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CA
    2,989,247</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Canada</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">IN
    467201</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">India</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK
    1252435</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">HK
    40026195</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy (DIV)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hong
    Kong</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA
    2017/08439</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">VEGFR-2
    Targeting DNA Vaccine for Combination Therapy</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">South
    Africa</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/06/2036</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>

  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="5" STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Family
    7 &#8212; VXM01 Tumor Expression: WO 2018/149982</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US
    10,980,868</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel
    VEGFR-2 Targeting Immunotherapy Approach</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/02/2038</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP
    18 704 568.7</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel
    VEGFR-2 Targeting Immunotherapy Approach</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EP</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/02/2038</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
    Examination</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JP
    2019-544614</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel
    VEGFR-2 Targeting Immunotherapy Approach</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Japan</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/02/2038</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Patent
    / <BR>
    Application No.</B></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title
    / Subject Matter</B></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Territory</B></FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center; width: 14%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Expiry</B></FONT></TD>
    <TD STYLE="border: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center; width: 17%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Status</B></FONT></TD></TR>


  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR 10-2019-7026398</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel VEGFR-2 Targeting Immunotherapy Approach</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Korea</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/02/2038</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Examination</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">KR 10-2024-7035606</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel VEGFR-2 Targeting Immunotherapy Approach (DIV)</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Korea</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/02/2038</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CN 201880012318.8</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel VEGFR-2 Targeting Immunotherapy Approach</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">China</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/02/2038</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Examination</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AU 2018222777</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel VEGFR-2 Targeting Immunotherapy Approach</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/02/2038</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ZA 2019/04883</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Novel VEGFR-2 Targeting Immunotherapy Approach</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">South Africa</FONT></TD>
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16/02/2038</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; padding: 3pt 4pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under Examination</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">In addition to
the foregoing, the VXM01 IP Family includes all Know-How, regulatory filings, clinical trial data, biological materials, and other proprietary
information relating to the VXM01 program in the possession or control of the Seller as of the Closing Date, whether or not separately
listed herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center; text-indent: 0pt">SCHEDULE 2</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center; text-indent: 0pt">ASSIGNED CONTRACTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">The following agreements
are assigned to the Buyer pursuant to Section 2.1 of this Agreement, to the extent transferable and subject to the receipt of any required
third-party consents:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; width: 40%; text-align: left"><B>Agreement</B></TD>
    <TD STYLE="border: Black 1pt solid; padding: 3pt; width: 15%; text-align: left"><B>Counterparty</B></TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 3pt; width: 15%; text-align: left; border-bottom: Black 1pt solid"><B>Date</B></TD>
    <TD STYLE="border-right: Black 1pt solid; border-top: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; width: 30%; text-align: left"><B>Consent Required</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: left">Master Service Agreement, Contract no. B087 (Storage Cellbank, Storage DP) </TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt; text-align: left">Richter Biologics </TD>
    <TD STYLE="border-bottom: Black 1pt solid; padding: 3pt; text-align: left">01.03.2010 </TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt; text-align: left">No clause found so consent is recommended </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center; text-indent: 0pt">SCHEDULE 3</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: center; text-indent: 0pt">PAYMENT INSTRUCTIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">All payments of
the Purchase Price (whether the full outstanding balance on the Full Payment Due Date or any Partial Payments made prior thereto) by the
Buyer to the Seller under Section 5 of this Agreement shall be made by wire transfer of immediately available funds to the following account,
or to such other account as the Seller may specify in writing no later than ten (10) Business Days prior to the relevant payment date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0pt">Bank Name: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0pt">Bank Address:
[&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0pt">SWIFT/BIC: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.8pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0pt">IBAN / Account
Number: [&#9679;]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0pt">Account Name:
VAXIMM AG</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0pt">Reference: OSR
Holdings APA &ndash; Purchase Price Payment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">Each payment shall
be made in United States Dollars (USD) and shall be free and clear of any bank charges or deductions, which shall be borne by the Buyer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt"></P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0pt; text-align: left; text-indent: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>osrh-20260527.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qRZo7xRiXhun8uNbXQsSamG2aPtypR1SYkxs2t8Hck6/y4hQpxzeS+wBbO28UwJ -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2026" xmlns:us-gaap="http://fasb.org/us-gaap/2026" xmlns:srt="http://fasb.org/srt/2026" xmlns:srt-types="http://fasb.org/srt-types/2026" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:OSRH="http://bellevuespac.com/20260527" elementFormDefault="qualified" targetNamespace="http://bellevuespac.com/20260527">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://bellevuespac.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="osrh-20260527_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="osrh-20260527_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="osrh-20260527_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2026" schemaLocation="https://xbrl.sec.gov/dei/2026/dei-2026.xsd" />
    <import namespace="http://fasb.org/us-gaap/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd" />
    <import namespace="http://fasb.org/us-types/2026" schemaLocation="https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2026" schemaLocation="https://xbrl.sec.gov/country/2026/country-2026.xsd" />
    <import namespace="http://fasb.org/srt/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd" />
    <import namespace="http://fasb.org/srt-types/2026" schemaLocation="https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd" />
    <element id="OSRH_CommonStockParValue0.0001PerShareMember" name="CommonStockParValue0.0001PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember" name="RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>osrh-20260527_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="osrh-20260527.xsd#Cover" roleURI="http://bellevuespac.com/role/Cover" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://bellevuespac.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="osrh-20260527.xsd#OSRH_CommonStockParValue0.0001PerShareMember" xlink:label="loc_OSRHCommonStockParValue0.0001PerShareMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_OSRHCommonStockParValue0.0001PerShareMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="osrh-20260527.xsd#OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember" xlink:label="loc_OSRHRedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_OSRHRedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus_40" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate_40" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName_40" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey_40" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber_40" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber_40" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode_40" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1_40" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2_40" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3_40" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown_40" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince_40" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry_40" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode_40" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion_40" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode_40" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber_40" xlink:type="arc" order="29" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="loc_deiExtension_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension_40" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications_40" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial_40" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer_40" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer_40" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle_40" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag_40" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol_40" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName_40" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle_40" xlink:type="arc" order="39" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation_40" xlink:type="arc" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers_40" xlink:type="arc" order="44" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus_40" xlink:type="arc" order="45" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent_40" xlink:type="arc" order="46" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory_40" xlink:type="arc" order="47" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness_40" xlink:type="arc" order="48" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany_40" xlink:type="arc" order="49" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod_40" xlink:type="arc" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard_40" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber_40" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany_40" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat_40" xlink:type="arc" order="54" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent_40" xlink:type="arc" order="55" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding_40" xlink:type="arc" order="56" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock_40" xlink:type="arc" order="57" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>osrh-20260527_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="osrh-20260527.xsd#OSRH_CommonStockParValue0.0001PerShareMember" xlink:label="OSRH_CommonStockParValue0.0001PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OSRH_CommonStockParValue0.0001PerShareMember" xlink:to="OSRH_CommonStockParValue0.0001PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OSRH_CommonStockParValue0.0001PerShareMember_lbl" xml:lang="en-US">Common stock, par value $0.0001 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="osrh-20260527.xsd#OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember" xlink:label="OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember" xlink:to="OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember_lbl" xml:lang="en-US">Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>osrh-20260527_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.5a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="osrh-20260527.xsd#Cover" roleURI="http://bellevuespac.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://bellevuespac.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="osrh-20260527.xsd#OSRH_CommonStockParValue0.0001PerShareMember" xlink:label="loc_OSRHCommonStockParValue0.0001PerShareMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_OSRHCommonStockParValue0.0001PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="osrh-20260527.xsd#OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember" xlink:label="loc_OSRHRedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_OSRHRedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2026/dei-2026.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.26.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 27, 2026</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 27,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OSR HOLDINGS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001840425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-5052822<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10900 NE 4th Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 2300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bellevue<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">425<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">635-7700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=OSRH_CommonStockParValue0.0001PerShareMember', window );">Common stock, par value $0.0001 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OSRH<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember', window );">Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OSRHW<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=OSRH_CommonStockParValue0.0001PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=OSRH_CommonStockParValue0.0001PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.26.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>2</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ea0293037-8k_osrhold.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://bellevuespac.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0293037-8k_osrhold.htm">ea0293037-8k_osrhold.htm</File>
    <File>osrh-20260527.xsd</File>
    <File>osrh-20260527_def.xml</File>
    <File>osrh-20260527_lab.xml</File>
    <File>osrh-20260527_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2026</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0293037-8k_osrhold.htm": {
   "nsprefix": "OSRH",
   "nsuri": "http://bellevuespac.com/20260527",
   "dts": {
    "inline": {
     "local": [
      "ea0293037-8k_osrhold.htm"
     ]
    },
    "schema": {
     "local": [
      "osrh-20260527.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd",
      "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd",
      "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd",
      "https://xbrl.sec.gov/country/2026/country-2026.xsd",
      "https://xbrl.sec.gov/dei/2026/dei-2026.xsd",
      "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "osrh-20260527_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "osrh-20260527_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "osrh-20260527_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 1,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 2,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2026": 2
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 2,
   "elementCount": 65,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2026": 27
   },
   "report": {
    "R1": {
     "role": "http://bellevuespac.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2026-05-27",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0293037-8k_osrhold.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2026-05-27",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0293037-8k_osrhold.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CityAreaCode",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "auth_ref": []
    },
    "OSRH_CommonStockParValue0.0001PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bellevuespac.com/20260527",
     "localname": "CommonStockParValue0.0001PerShareMember",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, par value $0.0001 per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CountryRegion",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentType",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Extension",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "OSRH_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://bellevuespac.com/20260527",
     "localname": "RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12bTitle",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "Security12gTitle",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementLineItems",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2026",
     "localname": "StatementTable",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "TradingSymbol",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2026",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://bellevuespac.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001213900-26-064037-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-26-064037-xbrl.zip
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MFJU:^BF9=#7\C\M06@A.>5,RNM68 "FB:"P-2X [H0[IV$S%9%PCNDEJD#9
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MQ4+INWNG;,0[532-,\?Q?YSJ)E/B/5/!_>Q=%7<OU>HW>*;BLF>*02!95K*
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MY9:E\!:EQ2U,W[9EZ7DIT5,;'U>>-LB45Q]$@)1S9[?D;[&$?X&)1:[*4R1
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M@E\PR*QTLQ2D'9YRU 4"H$5=140:NM^DN(F"+"0=BMX3UDJ-GZ".Y$>$773
MD 6^JI-S>O8G/ V/S\>SBXZ#T([Z0.+#?M JZBT<9D1D7@24Y88*6UV]28D
M6D)^ #O%;)*5%>00!&9B$$4]^NK&#3*BE](P3(::A,F2DV1H-_.!C@BM6:S0
M1AU$7N];&-T&LC>0O5E4#$>U#UI-=)L\)Y/]8WBB#'ON?0;864KO?)/LK*N;
MZ_<;9X\Z'X]/CZ^.STXOZ6(,JGB%MLMV(K*$1'1B-/6: 7H$OT2^!'8R'B8*
M>DFZIR,IW9!L#,79ZX+P>[LN#MV1GY*<VU.WTC@:)\L"[;S'@M2<>+'?9:$=
M?AGR1&=@]'+9/A\\J/[?')J>M76&)U)+&(9!IU[#14P4ZP)Q883B)\H"('*>
M@VP0$3Z.%3;R-\QV650%9@_(B79G]4G9:!)R3VJ##6[IV*$K$\5"4<F)0GU%
MO483(-;&@ZR+CW"YDG"27,0ABO 9B-5[J4=H.SB]$!NZ(A <DH2NG3U;1S.-
M473+BH&6U^$RS\T24X@W>8P;@OY.@@%.,@H0_FF2;KYJM]>2UBR]!FEK<%W6
M,&XBLG(F$@00'UF!@[8O>A,0DFBE<M%Z<31+_]W<66]L5SCX:\T]NI!)2-'Q
M(J(A%D++L*V#$.7%0[5FB4'5B@80+ K&[^3+FS#+=V.0= =**@C0STH =^E=
MRUX&;+]5LA$4!DS8XQ&Z4^@A_#N;G^NU7.%G0@.1#5[9AP^,2S-DVL(BC@<
MU%&8R1 @D:@M 4$UB= V B=3NC&*%<;[#&',N*3&&;_6:]JL#S_C1>:=;&4(
M K<;*>')$)#47&'UD;[ULU$26@ E_KQE>WEL[%7LJZV9]M4#\0<(E_CSR[.T
MFJNAU^% 7(U'\+IM("/?.Q"G[E#R6IU&N *MDFU4WX6_O#2+[?+0_R)@^ .
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M$<H;]\[D'OE\@;NT.7>7#OFHB0MU$/-)SS)<_ IS1'G^TW,^<4%0B_$LW?C
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MFOX4J6U\.#OZ"VT\&Y^O3KZ\__]02P,$%     @ &8K"7 N)?[[C P  . \
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MZ!T$J+N_U]\EQ\T/\V=I])'_ U!+ P04    "  9BL)<_/M59R,,   HD0
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M-6X4>5'[;<YT$G(MJHLM8S%C<11$:427G\3%)X^PJ50FD2T@8(,%#4V%%RB
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M)8&FR3OS;?Z-_6'_MH(Y\@]02P$"% ,4    "  9BL)<3/Z&VO 9  #GD@
M&               @ $     96$P,CDS,#,W+3AK7V]S<FAO;&0N:'1M4$L!
M A0#%     @ &8K"7/1+9M[B10  Y;L" !4              ( !)AH  &5A
M,#(Y,S S-S Q97@Q,"TQ+FAT;5!+ 0(4 Q0    ( !F*PEP+B7^^XP,  #@/
M   1              "  3M@  !O<W)H+3(P,C8P-3(W+GAS9%!+ 0(4 Q0
M   ( !F*PER$,S"0%@D  !)I   5              "  4UD  !O<W)H+3(P
M,C8P-3(W7V1E9BYX;6Q02P$"% ,4    "  9BL)<_/M59R,,   HD0  %0
M            @ &6;0  ;W-R:"TR,#(V,#4R-U]L86(N>&UL4$L! A0#%
M  @ &8K"7*6]:?1@"   K&,  !4              ( !['D  &]S<F@M,C R
C-C U,C=?<')E+GAM;%!+!08     !@ & )$!  !_@@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ea0293037-8k_osrhold_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:OSRH="http://bellevuespac.com/20260527"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="osrh-20260527.xsd" xlink:type="simple"/>
    <context id="AsOf2026-05-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
        </entity>
        <period>
            <startDate>2026-05-27</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <context id="From2026-05-272026-05-27_custom_CommonStockParValue0.0001PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OSRH:CommonStockParValue0.0001PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-27</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <context id="From2026-05-272026-05-27_custom_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001840425</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">OSRH:RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-05-27</startDate>
            <endDate>2026-05-27</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="AsOf2026-05-27" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2026-05-27" id="Fact000004">0001840425</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2026-05-27" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2026-05-27" id="Fact000010">2026-05-27</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2026-05-27" id="Fact000011">OSR HOLDINGS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2026-05-27" id="Fact000012">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2026-05-27" id="Fact000013">001-41390</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2026-05-27" id="Fact000014">84-5052822</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2026-05-27" id="Fact000015">10900 NE 4th Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2026-05-27" id="Fact000016">Suite 2300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2026-05-27" id="Fact000017">Bellevue</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2026-05-27" id="Fact000018">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2026-05-27" id="Fact000019">98004</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2026-05-27" id="Fact000020">425</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2026-05-27" id="Fact000021">635-7700</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2026-05-27" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2026-05-27" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2026-05-27" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2026-05-27" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="From2026-05-272026-05-27_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000026">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2026-05-272026-05-27_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000027">OSRH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2026-05-272026-05-27_custom_CommonStockParValue0.0001PerShareMember"
      id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="From2026-05-272026-05-27_custom_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember"
      id="Fact000029">Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="From2026-05-272026-05-27_custom_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember"
      id="Fact000030">OSRHW</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="From2026-05-272026-05-27_custom_RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember"
      id="Fact000031">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2026-05-27" id="Fact000032">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="AsOf2026-05-27" id="Fact000033">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
